D
Donald J. Hillebrand
Researcher at Scripps Health
Publications - 4
Citations - 976
Donald J. Hillebrand is an academic researcher from Scripps Health. The author has contributed to research in topics: Hepatic encephalopathy & Cirrhosis. The author has an hindex of 2, co-authored 4 publications receiving 857 citations.
Papers
More filters
Journal ArticleDOI
Rifaximin treatment in hepatic encephalopathy.
Nathan M. Bass,Kevin D. Mullen,Arun J. Sanyal,Fred Poordad,Guy W. Neff,Carroll B. Leevy,Samuel H. Sigal,Muhammad Y. Sheikh,Kimberly Beavers,Todd Frederick,Lewis W. Teperman,Donald J. Hillebrand,Shirley Huang,Kunal Merchant,Audrey L. Shaw,Enoch Bortey,William P. Forbes +16 more
TL;DR: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo, and also significantly reduced the risk of hospitalization involving hepaticEncephalopathy.
Journal ArticleDOI
222 chronic administration of rifaximin for the maintenance of remission of hepatic encephalopathy: a subgroup analysis of a phase 3 trial
Arun J. Sanyal,Nathan M. Bass,Lewis W. Teperman,Samuel H. Sigal,Donald J. Hillebrand,Kunal Merchant,Shirley Huang,Audrey L. Shaw,Enoch Bortey,William P. Forbes +9 more
Journal ArticleDOI
Formal heparin anticoagulation protocol improves safety of charcoal-based liver-assist treatments.
Donald J. Hillebrand,Kevin Hill,Ke-Qin Hu,Marge Strutt,Barry Wilson,Alfred Cottrell,Sigmund Teichman,Karen Hay,Brian S. Bull +8 more
TL;DR: Anticoagulation using ACT monitoring, heparin dose-response curves, and a target ACT of 300 seconds improves the safety of LDU treatments.